Proactive Investors - Run By Investors For Investors

Genus upgraded to ‘buy’ by Peel Hunt after share placing

The placing proceeds will ensure balance sheet flexibility to continue to invest in the business and to take advantage of infill acquisition opportunities, Peel Hunt analysts said
Genus upgraded to ‘buy’ by Peel Hunt after share placing
Peel Hunt said the current share price was an attractive entry point into a high quality business

Genus PLC (LON:GNS) was upgraded to a ‘buy’ from a ‘hold’ rating by broker Peel Hunt after the animal genetics company said on Friday it had raised of £68mln through a share placing.

Genus said 3.1mln new shares were issued to new and existing investors at a price of 2,200p per placing share.

READ: Genus raises of £68mln through share placing

“The proceeds will ensure balance sheet flexibility to continue to invest in the business and to take advantage of infill acquisition opportunities,” Peel Hunt analysts wrote in a note to clients.

“The raise is slightly dilutive (c3% in the short term) but should be materially accretive as the company strengthens its strategic position and breeding capacity.”

Genus’s share price is 25% off the peak it reached last July, triggered by the outbreak of African swine fever (ASF) in China.

Peel Hunt said the current share price was an attractive entry point into a high-quality business with attractive long-term growth potential combined with the transformative opportunity in gene editing. Peel Hunt maintained its 2,600p target price.

Genus was earlier this week upgraded to a ‘buy’ from a ‘hold’ rating by broker Kepler Chevreux who believes the fall in the animal genetics company’s share price on the back of fears over the outbreak of African swine fever has been overdone.

Genus shares were 5.6% down at 2,258.0p in mid-morning trade.

View full GNS profile View Profile

Genus Timeline

Related Articles

man with erectile dysfunction
April 27 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
salmon
January 31 2019
Long-term fundamentals remain firmly in the seafood specialist's favour.
blood samples in test tubes
October 26 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use